(Q24244302)

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB3

Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB3

Nitazoxanide for the treatment of Clostridium difficile colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB3

Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB3

Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB3

A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated diarrhoea

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB3

Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB3

Frequent emergence of resistance in Clostridium difficile during treatment of C. difficile-associated diarrhea with fusidic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB3

The transitive fallacy for randomized trials: if A bests B and B bests C in separate trials, is A better than C?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB3

Clinical practice. Antibiotic-associated diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB3

Diagnosis and treatment of Clostridium difficile colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB3

Increased incidence of Clostridium difficile-associated diarrhea following decreased restriction of antibiotic use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB3

Clostridium difficile colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB3

How should we respond to the highly toxogenic NAP1/ribotype 027 strain of Clostridium difficile?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB3

An epidemic, toxin gene-variant strain of Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB3

Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB3

Quebec to report on Clostridium difficile in 2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB3

Severe Clostridium difficile colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB3

Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB3

Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB3

Oral bacitracin vs vancomycin therapy for Clostridium difficile-induced diarrhea. A randomized double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB3

7 January 2021

Clostridium difficile colitis: an increasingly aggressive iatrogenic disease?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB3

7 January 2021

Recommendations for preventing the spread of vancomycin resistance: Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB3

7 January 2021

Recurrent Clostridium difficile disease: epidemiology and clinical characteristics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB3

7 January 2021

Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB3

7 January 2021

Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile-associated diarrhea

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB3

7 January 2021

Ten Years of Prospective Clostridium difficile-Associated Disease Surveillance and Treatment at the Minneapolis VA Medical Center, 1982–1991

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB3

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB3

1 reference

7 January 2021

Clostridium difficile-associated diarrhea: epidemiology, risk factors, and infection control

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB3

7 January 2021

Clostridium difficile-Associated Diarrhea and Colitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB3

7 January 2021

Clinical and laboratory observations in Clostridium difficile colitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB3

7 January 2021

Clostridium difficile: clinical considerations.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB3

7 January 2021

Clostridium difficile and its cytotoxin in feces of patients with antimicrobial agent-associated diarrhea and miscellaneous conditions.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB3

7 January 2021

Randomised controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhoea

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB3

7 January 2021

Treatment of Clostridium difficile associated diarrhea and colitis with an oral preparation of teicoplanin; a dose finding study. The Swedish CDAD Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB3

7 January 2021

Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB3

7 January 2021